Surgalign and Aziyo Biologics updated their U.S. distribution agreement and expanded product offering whereby Aziyo will provide ViBone® Moldable to Surgalign to support spinal fusion. In 2018, the two partnered on ViBone cellular bone matrix.
Like ViBone, ViBone Moldable next-generation viable cell bone matrix is processed to protect and preserve the health of native bone cells to potentially enhance new bone formation. ViBone delivers osteoinduction, osteoconduction and osteogenesis along with excellent handling and cohesive properties.
“ViBone Moldable combines Aziyo’s expertise in viable cellular allograft bone matrix processing with handling enhancements for a better operating room experience,” said Terry Rich, President and Chief Executive Officer of Surgalign. “With this addition, Surgalign continues to focus on delivering innovative solutions for improved patient outcomes.”
Ron Lloyd, President and CEO of Aziyo, said, “The orthopedic and spinal repair market is estimated to be a $2 billion market opportunity, with 1.5 million annual orthopedic and spinal repair procedures using biologic materials. We are confident that ViBone Moldable will be a great addition to the Surgalign portfolio of viable bone matrices addressing this significant market need.”